Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Analgesic Effect of Midazolam and Ketamine as an Additive to Intrathecal Bupivacaine in Patients Undergoing Cesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* patients with American Society of Anesthesiologists(ASA) physical status I and II, undergoing elective cesarean section~Exclusion Criteria:~* significant coexisting disease such as hepato-renal and cardiovascular disease~* any contraindication to regional anesthesia such as local infection or bleeding disorders~* allergy to ketamine or midazolam~* long-term opioid use or a history of chronic pain.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine (Type: ACTIVE_COMPARATOR): The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally .
- midazolam (Type: ACTIVE_COMPARATOR): The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
- placebo (Type: PLACEBO_COMPARATOR): The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .

Based on this trial design, predict the completion outcome and termination type (if applicable).